Collegium Pharmaceutical Inc Cash Flow Conversion Efficiency
Collegium Pharmaceutical Inc cash flow conversion efficiency. Based on the latest financial reports, Collegium Pharmaceutical Inc (COLL) has a cash flow conversion efficiency ratio of 0.285x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($78.44 Million) by net assets ($274.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Collegium Pharmaceutical Inc (2013–2024)
Cash flow conversion efficiency of Collegium Pharmaceutical Inc from 2013 to 2024. This chart illustrates how Collegium Pharmaceutical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Collegium Pharmaceutical Inc stock price today for real-time trading data and today's change.
Collegium Pharmaceutical Inc Cash Flow Conversion Ratio Explained
Collegium Pharmaceutical Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Collegium Pharmaceutical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Collegium Pharmaceutical Inc ranked by their cash flow conversion efficiency. Also see COLL stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trident Digital Tech Holdings Ltd American Depository Shares
NASDAQ:TDTH
|
0.724x |
|
Thunder Tiger Corp
TW:8033
|
-0.014x |
|
Hangzhou Jingye Intelligent Technology Co. Ltd. A
SHG:688290
|
N/A |
|
Medplus Health Services Limited
NSE:MEDPLUS
|
0.159x |
|
Hubei Huaqiang High-Tech Co. Ltd. A
SHG:688151
|
N/A |
|
Logistea AB Series B
ST:LOGI-B
|
0.017x |
|
ZhuZhou QianJin Pharmaceutical Co Ltd
SHG:600479
|
0.084x |
|
Zhejiang Grandwall Electric Science&Technology Co Ltd Class A
SHG:603897
|
0.061x |
Annual Cash Flow Conversion Efficiency for Collegium Pharmaceutical Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Collegium Pharmaceutical Inc from 2013 to 2024. Review COLL free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $228.84 Million | $204.98 Million | 0.896x | -36.29% |
| 2023-12-31 | $195.43 Million | $274.75 Million | 1.406x | +120.50% |
| 2022-12-31 | $194.84 Million | $124.23 Million | 0.638x | +24.94% |
| 2021-12-31 | $202.93 Million | $103.56 Million | 0.510x | +1.06% |
| 2020-12-31 | $186.03 Million | $93.94 Million | 0.505x | +58.92% |
| 2019-12-31 | $87.43 Million | $27.78 Million | 0.318x | -82.82% |
| 2018-12-31 | $91.58 Million | $169.39 Million | 1.850x | +387.24% |
| 2017-12-31 | $104.08 Million | $-67.02 Million | -0.644x | -15.74% |
| 2016-12-31 | $134.91 Million | $-75.05 Million | -0.556x | -119.45% |
| 2015-12-31 | $85.07 Million | $-21.57 Million | -0.254x | -117.29% |
| 2014-12-31 | $-12.24 Million | $-17.95 Million | 1.466x | +149.51% |
| 2013-12-31 | $5.58 Million | $-16.53 Million | -2.961x | -- |
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine… Read more